Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma.
Management Board ǀ Apogenix
The Handbook of Board Governance: A Comprehensive Guide for Public, Private, and Not-for-Profit Board Members: Leblanc, Richard: 9781118895504: Books
Apogenix Company Profile: Valuation, Funding & Investors
Clinical Candidates ǀ Apogenix
Regulatory chromatin rewiring promotes metabolic switching during adaptation to oncogenic receptor tyrosine kinase inhibition
The Perfect Corporate Board: A Handbook for Mastering the Unique Challenges of Small-Cap Companies: 9780071799546: Epstein, Adam: Books
Investors ǀ Apogenix
.jpg)
Management Board ǀ Apogenix
Contact Request ǀ Apogenix
